I nsulin-dependent diabetes mellitus (IDDM), 3 type 1 diabetes, is an autoimmune disease in which the insulin-producing pancreatic ␤ islets are destroyed by T cells (1) (2) (3) (4) (5) (6) (7) (8) . Studies in nonobese diabetic (NOD) mice, an animal model for the human disease, have shown that they develop spontaneous proliferative T cell response to several ␤ cell autoantigens and resulted in ␤ islet destruction (1, 2, 4 -8) . It is hypothesized that diabetes development in NOD mice is due to the loss of tolerance to autoantigens and a biased activation of Th1 cells may enhance diabetes, whereas Th2 cells inhibit the disease (2, 5, 9) . Therefore, inhibition of Th1 cell-mediated immune response and restoration of tolerance to autoantigens and induction of Th2 cell differentiation may prevent disease development (5, 10) . In support of this hypothesis, previous studies have shown that generation of CD4 ϩ Th2 cells may regulate IDDM development by secreting IL-4 and IL-0 that can inhibit Th1 cell differentiation (1, 2, 5, 11) .
Recently, a selective approach using specific autoantigens, e.g., glutamic acid decarboxylase (GAD) and its peptides, to treat animals was used to immunomodulate IDDM (12) (13) (14) (15) . Despite the effectiveness of this approach, the mechanisms underlying Agbased immunotherapies remain largely elusive. Regulation of IDDM by treatment of animals with Ags may be epitope dependent and correlate with an induction of Th2 cells (15, 16) . However, Th2 cells can also cause the development of the disease (17, 18) . Furthermore, a shift to Th2 cells after peptide treatment of patients may induce deleterious allergic or autoimmune response (19) . Therefore, a detailed understanding of the nature of the T cells induced in animals treated with autoantigens should help us better understand the immunoregulatory mechanisms, allowing for the design of a more effective and less harmful immunotherapy.
We have shown that a recently developed technique (20, 21) could be used to generate class II MHC I-Ag7 tetramers and subsequently detect and isolate Ag-specific T cells from NOD mice (22, 23) . It has been possible to generate autoantigen-specific T cell lines in vitro without the use of tetramer (15, 16, 24, 25) . However, using tetramers we can isolate a large number of Agspecific T cells with FACS. By culturing these T cells in a condition that is not biased toward either Th1 or Th2 cells, they may represent the Ag-specific T cell population generated in vivo. We now report the use of new class II MHC tetramers to isolate CD4 ϩ T cells from NOD mice treated with two GAD peptides, p206 and p221. We also studied T cells from BALB/c mice because these mice express the class II MHC I-Ad molecules that are very similar to the I-Ag7 molecules expressed in NOD mice with the only difference being present in their ␤1 domain of the ␤-chain. It would be interesting to find out whether I-Ad and I-Ag7 selected T cells specific for the same GAD peptide have the same functions. Our results demonstrated that Ag treatment induced various Th2 and T regulatory type 1 (Tr1) cells specific for the two GAD peptides in NOD mice dependent on the peptide used. Based on their cytokine secretion profiles, immunization of NOD mice with the same peptide induced different T cell subsets than in BALB/c mice. Studies on the isolated NOD mouse tetramer ϩ T cells showed that they could inhibit diabetes development. Further studies showed that the tetramer ϩ cells could function as regulatory T cells by secreting cytokines and suppressing the proliferation of other T cells in vitro. They could also block the migration of diabetogenic T cells in vivo.
Materials and Methods

Mice
The NOD and BALB/c mice were purchased from The Jackson Laboratory (Bar Harbor, ME). The BDC2.5-transgenic mice were a gift from Drs. D. Mathis and C. Benoit (26) . All animals were housed in a specific pathogenfree environment in the animal facility at the Beckman Research Institute, City of Hope.
Peptides and immunization
GAD65 p206 (TYEIAPVFVLLEYVT), p221 (LKKMREIIGWPGGSG), and the previously published BDC2.5 T cell-stimulating peptide p79 (1040 -79) (27) were synthesized at the Beckman Research Institute, City of Hope, and purified using reversed-phase HPLC to a purity of Ͼ98%. Animals were injected i.p. with 100 g of a peptide emulsified in an equal volume of IFA (Sigma-Aldrich, St. Louis, MO) on days 0 and 7. Spleens were removed from animals on day 14 for further analyses.
Production of class II MHC tetramers
This method has been described previously (20 -22) . Production and initial use of the tetAg7/p206 and tetAg7/p79 has been previously described (22, 23) . The C-terminal end of the ␣-and ␤-chain of I-Ad/p206 heterodimer contained a leucine zipper for heterodimer pairing (28) .
Isolation and staining of tetramer ϩ T cells and cytokine assays
Splenocytes were pooled from at least four immunized animals and cultured in Click's medium (Life Technologies, Grand Island, NY) plus peptide for 3 days. Live cells were further incubated in IL-2/RPMI 1640 medium before being separated into tetramer ϩ and tetramer Ϫ cells using FACS and magnetic beads (Miltenyi Biotec, Auburn CA). Both tetramer ϩ and tetramer Ϫ cells were maintained in the IL-2 medium and, for longer cultures, the tetramer ϩ cells were stimulated with the Ag in the IL-2 medium 2-3 wk after the last Ag stimulation in vitro. The tetramer Ϫ cells were maintained in the same culture condition without the GAD peptides.
Staining of cells using tetramers has been described previously (22) . Briefly, T cells were stained with PE-labeled tetramers plus the anti-TCR C␤ Ab, H57, at 37°C for 2 h and analyzed by FACS using FACSCalibur (BD Biosciences, San Jose, CA) (29) . All of the Abs used for FACS and for in vitro inhibition assays were purchased from BD PharMingen (San Diego, CA).
The IL-2 bioassay has been described previously (22) . Capture ELISA (assay kit from BD PharMingen or from Promega, Madison, WI) was used to measure the amount of cytokines according to the manufacturer's instruction using cell culture supernatant harvested after incubating cells with Ags for 24 h. The GAD65 protein was purchased from Diamyd Diagnostic (Stockholm, Sweden).
Intracellular cytokine staining
Intracellular cytokine staining (ICS) was performed according to a previously described method (30) . Briefly, T cells were incubated with PMA plus ionomycin and brefeldin A, stained with surface Abs, fixed with paraformaldehyde, and resuspended in 0.1% saponin buffer (w/v) (SigmaAldrich). The cells were then intracellular stained using Abs against cytokines or negative isotype control Abs (BD PharMingen).
Adoptive transfer of T cells into NOD/scid mice and migration inhibition assays
Four-to 7-wk-old NOD/scid mice received a single i.v. injection of tetramer ϩ cells, tetramer ϩ cells plus NOD splenocytes, or NOD splenocytes alone. Recipient mice were considered diabetic when mice were glycosuric for 2 consecutive weeks.
To determine the in vivo inhibitory effect of tetramer ϩ T cells on the migration of adoptively transferred BDC2.5 T cells, the BDC2.5 mouse splenocytes (1 ϫ 10 7 /mouse) were mixed with equal numbers of the tetramer ϩ T cells and then cotransferred into NOD/scid mice. In addition, the tetramer ϩ T cells were preactivated with PMA/ionomycin (50 and 2500 ng/ml) for 16 h, washed, and cultured with the BDC2.5 splenocytes for 2 h before being cotransferred into NOD/scid mice. Cells from lymph nodes (axillary, brachial, inguinal, lumbar, and caudal nodes) were isolated and pooled together from adoptively transferred mice at 4 and 24 h after the transfer and stained with anti-CD4 Ab and tetAg7/p79 (23) . Pancreatic lymph nodes were also removed, but the total number of cells was too low to show reliably the presence of BDC2.5 cells.
CFSE labeling
CD4
ϩ T cells from BDC2.5 TCR-transgenic mouse spleens were purified using magnetic beads (Miltenyi Biotec) and labeled with CFSE. Briefly, CD4
ϩ T cells in serum-free PBS were incubated with CFSE (0.8 M) for 10 min at 37°C. After washing, the labeled CD4 ϩ BDC2.5 T cells were used for further analyses.
In vitro inhibition assays using cocultures
CFSE-labeled CD4
ϩ T cells from BDC2.5 mice (the target cells) were cultured in the absence of tetramer ϩ cells and 1) without peptides or 2) with p79 alone or together with GAD peptides. The CFSE-labeled cells were also cultured with either N221 ϩ or N206 ϩ cells plus p79 and GAD peptides. Irradiated (3000 rad) NOD mouse CD4 Ϫ cells were used as APCs. After being cultured for 4 days, cells were stained with the tetAg7/ p79 tetramer (23) . The effect of tetramer ϩ cells on BDC2.5 T cell proliferation was analyzed using FACS to determine whether the CFSE intensity was altered as compared with that of control cells.
Transwell assays
NOD splenocytes were cultured outside of Transwells (Corning, Corning, NY) in the lower well using a 24-well plate. Tetramer ϩ cells were cultured in the Transwell (the upper well) in the presence of irradiated APCs. All of the cells were activated with 100 ng/ml PMA and 5000 ng/ml ionomycin in the culture. After 72 h, [ 3 H]thymidine was added to the lower well and the cells were harvested 24 h later. Thymidine incorporation was determined using a Wallac cell harvester (Wallac, Gaithersburg, MD).
To determine the cytokine effect on target cell proliferation, anticytokine Abs were also added to the Transwell assays. The procedures were the same as described above, except that a saturating amount of Abs (20 g/ml) was added to the culture.
Results
Isolation of CD4
ϩ tetramer ϩ T cells
To isolate GAD peptide-specific CD4 ϩ T cells derived from NOD mice and from BALB/c mice, we have produced I-Ag7 (tetAg7/ p206 or tetAg7/p221) and I-Ad (tetAd/p206 or tetAd/p221) tetramers bound to GAD p206 or p221. We chose these two GAD peptides because they are major T cell epitopes and may play important roles in IDDM (12-14, 31, 32) . Treatment of NOD mice with GAD protein or peptides reduced the incidence of diabetes (12) (13) (14) 33) . To understand the function of regulatory T cells induced in Ag-treated animals and their roles in regulating IDDM development, we isolated CD4 ϩ tetramer ϩ T cells from p206-or p221-immunized NOD mice (N206 ϩ or N221 ϩ cells). In addition to NOD mice, we also immunized BALB/c mice, whose cells express class II MHC I-Ad molecules. Both I-Ad and I-Ag7 use the same ␣-chain and their ␤-chains differ from each other only in the ␤1 domain. Furthermore, immunization of NOD and BALB/c mice could induce Ag-specific T cell responses. Therefore, despite their different genetic background, immunization of BALB/c mice with the same GAD peptides allows us to characterize peptidespecific T cells (B206 ϩ or B221 ϩ cells) selected by I-Ad. We have repeated the experiments of mouse immunization and T cell isolation and have isolated two to three tetramer ϩ T cell lines from peptide-treated mice for further analyses. Consistent with previous studies, NOD mice immunized with IFA alone could still develop diabetes (12, 14, 15) . However, diabetes development in NOD mice could be inhibited by immunization with IFA plus the GAD peptides. Therefore, treatment of NOD mice with the GAD peptides and not the IFA may induce regulatory T cells that can inhibit diabetes development.
The I-Ag7 and I-Ad tetramers were Ag specific, as they did not detect a significant number of tetramer ϩ T cells specific for the other peptide (Fig. 1A) . The isolated tetramer ϩ T cells were also Ag specific because only tetramer ϩ but not tetramer
Ϫ , and B221 Ϫ cells) derived from NOD or BALB/c mice responded to both synthetic (Fig. 1, B and D) and recombinant (Fig. 1, C and E) peptides and secreted IL-2. These results suggested that the response was not unique to peptides made by chemical synthesis which may lead to altered peptide display by class II MHC (34) . In addition, tetramer ϩ T cells specific for either p206 or p221 from BALB/c mice secreted 2-to 3-fold more IL-2 than did tetramer ϩ T cells from NOD mice.
Tetramer ϩ T cells showed different cytokine secretion profiles
We then determined the cytokine secretion profiles of Ag-stimulated tetramer ϩ T cells. The cells were cultured in medium supplemented with IL-2 without selectively promoting either Th1 or Th2 cell differentiation. ELISA analyses showed that tetramer ϩ but not tetramer Ϫ T cells secreted IFN-␥ and IL-4 in response to the Ags. N206
ϩ cells secreted 2-to 3-fold less IFN-␥ but 2-fold more IL-4 than did B206 ϩ cells (Fig. 2, A and B) . In contrast, N221 ϩ cells secreted ϳ4-fold more IFN-␥ and 1.5-fold more IL-4 than did B221 ϩ cells (Fig. 2, C (Fig. 3) . The explanation for this observation is not clear. Taken together, the results showed that N206 ϩ cells were biased toward Th2-like cells compared with B206 ϩ cells. In contrast, N221 ϩ cells were more like Th1 cells compared with B221 ϩ cells. On the other hand, the cells from BALB/c mice are essentially nonpolarized. Additionally, a small population of these tetramer ϩ cells (0.3-0.5%) might coproduce IL-4/IFN-␥, suggesting that they are Th0 cells (data not shown).
Additional cytokine secretion assays showed that both N206 Ags were 5-fold serially diluted from 25 g/ml (synthetic peptides) or 25 g/well (recombinant peptides). Cell culture supernatant was harvested after 24 h and HT2 cells were used as the indicator in a MTT assay. The results were an average of at least four independent experiments (except for B206 ϩ cells which were from two experiments).
FIGURE 2. ELISA of tetramer ϩ T cells. A-D, ELISA of IFN-␥ and IL-4 production by Ag-stimulated tetramer
ϩ and tetramer Ϫ T cells derived from NOD or BALB/c mice. Cells were stimulated with various concentrations of peptides as described in Fig. 1 . Cell culture supernatant was harvested after 24 h for ELISA. The results shown are an average of at least four independent experiments. The lower detection limit of ELISA was 8 pg/ml for IL-4 and 30 pg/ml for IFN-␥. E, The calculated IFN-␥:IL-4 ratio of the amount of cytokines that were secreted at the Ag concentration of 25 g/ml is shown.
TGF-␤ (Fig. 4, C and D). Additional ICS studies showed that essentially all IL-4 producing N206
ϩ or N221 ϩ cells coproduced IL-10, indicating that they represent Th2 cells (Fig. 4E) . Interestingly, IFN-␥-producing N206 ϩ cells also produced IL-10, suggesting that they probably are not the classical Th1 cells but more likely to be the Tr1 cells as described before (35) . Additionally, the majority of IFN-␥-producing N221 ϩ cells coproduced IL-10 while a small portion of the cells did not, indicating that the former cells were like Tr1 cells and the later ones like Th1 cells. Therefore, the IFN-␥-secreting N221 ϩ cells were mostly Tr1 cells rather than Th1 cells. The results also showed that N206 ϩ cells contained nearly 2-fold more Th2 cells than did N221 ϩ cells, whereas N221 ϩ cells contained 40-fold more Tr1 cells and 10-fold more Th1 cells than did N206 ϩ cells. Therefore, GAD p206 and p221 could stimulate T cells that differ from each other in that they contained various Th and Tr cell populations. N206 ϩ cells were relatively more biased toward Th2 cells and N221 ϩ cells toward Tr1 cells. These results also suggest that the indication of a Th1, Th2, or Tr1 cell response can be better defined with experiments, including both ICS and ELISA.
Because the tetramer ϩ T cell lines were derived from T cells of immunized mice and were restimulated in vitro with the peptides, we also studied the cytokine secretion profile of T cells derived from GAD protein-immunized NOD and BALB/c mice before further in vitro Ag stimulation. Our results demonstrated that T cells isolated from GAD-immunized NOD mice secreted a significant amount of IFN-␥, IL-4, and IL-10 after they were restimulated in vitro by GAD and p206 (Fig. 5, A-C) . When the T cells were restimulated with p221, they also secreted a large amount of IFN-␥ and IL-10 but secreted a small amount of IL-4. Although the total amount of cytokines secreted by these mixed populations of T cells (usually containing Ͻ3% tetramer ϩ cells) was smaller than that of purified tetramer ϩ cells shown above in Figs. 2 and 4 , the amount of cytokines secreted at a per cell base is comparable to that of tetramer ϩ cells. Furthermore, the IFN-␥:IL-4 ratio of T cells was 3.3, 0.4, and 4.1 from GAD-immunized mice in response to GAD (50 g/ml), p206 and p221 (40 g/ml), respectively, similar to that of tetramer ϩ cells in response to the peptides (25 g/ml) shown above (Fig. 2E) . These results suggest that the cytokine secretion profile of NOD mouse T cells specific for p206 or p221 remain the same before and after they were restimulated in vitro with the peptides. Additionally, both N206 ϩ and N221 ϩ T cells could respond to the GAD protein and secrete IL-2, suggesting that these cells were similar to those T cells that develop spontaneously in NOD mice (Fig. 5D ). On the other hand, the T cells from GAD protein-immunized BALB/c mice did not show a significant cytokine secretion response to GAD, p206, and p221 (data not shown). The reason for this weak response is not clear. It could be that the frequency of T cells specific for these peptides in GAD-immunized BALB/c mice was too low to show a significant response if the cells were not restimulated with the peptides and further expanded in vitro. Additionally, as we have shown in this report, the number of Ag-specific T cells from GAD peptide-immunized BALB/c mice could be significantly increased and isolated using the tetramers after they were further cultured in vitro with the peptides.
Adoptive transfer of N206 ϩ and N221 ϩ T cells reduced diabetes incidence
To determine the role of N206 ϩ and N221 ϩ T cells during diabetes development, we transferred these cells into NOD/scid mice. Because NOD/scid mice do not have T and B cells and do not develop diabetes, the initial studies will show whether the transferred tetramer ϩ T cells alone can induce diabetes. Nondiabetic NOD mouse splenocytes were used as the control. The results showed that although all of the mice that received splenocytes developed diabetes, none of those receiving tetramer ϩ T cells alone became diabetic (Fig. 6A) onset (Fig. 6B) . The results were essentially identical to those of the double-transferred mice receiving N206 ϩ cells in combination with NOD splenocytes. In addition, nondiabetic animals that received T cells did not develop detectable insulitis (data not shown), suggesting that the tetramer ϩ T cells may prevent cell infiltration into islets.
We have performed additional experiments to determine whether the disease suppression was specifically induced by N206 ϩ and N221 ϩ cells but not by other activated NOD mouse T cells. First, we studied whether Con A-stimulated NOD splenocytes, in addition to T cells activated by the GAD peptides, were able to suppress diabetes development in adoptive transfer experiments. The results showed that, unlike the tetramer ϩ T cells, Con A-activated cells did not inhibit diabetes development and all of the mice receiving these cells developed diabetes by the age of 26 wk (Fig. 6C) . Second, in a separate study, we have generated a new I-Ag7 tetramer (tetAg7/p79) that could detect essentially all of the BDC2.5 T cells from BDC2.5 TCR-transgenic NOD mice (23) . BDC2.5 T cells were diabetogenic CD4 ϩ T cells and BDC2.5 TCR-transgenic NOD mice could develop an aggressive form of diabetes (26, 36) . The tetAg7/p79 tetramer contains the p79 peptide that is highly active in stimulating BDC2.5 T cells and its sequence is unrelated to the GAD p206 and p221 peptides (27) . Therefore, p79 can serve as a good control peptide and tetAg7/p79 as a good control tetramer containing an irrelevant peptide. We have isolated BDC2.5 T cells from BDC2.5 TCR-transgenic mice with this tetramer, although not all CD4 ϩ T cells in these animals bear the BDC2.5 TCR. The BDC2.5 T cells were stimulated with p79 in vitro and transferred into NOD/scid mice. The results showed that recipient mice that received p79-activated but not nonactivated BDC2.5 T cells developed diabetes within 10 days after adoptive transfer of the cells (Fig. 6D) . Third, we have used tetAg7/p79 to isolate and characterize NOD mouse CD4 ϩ T cells specific for p79 (23) . In those studies we found that tetAg7/p79 ϩ T cells did not inhibit diabetes development after being cotransferred with NOD splenocytes into NOD/scid mice. Altogether, these in vivo adoptive transfer experiments showed that N206 ϩ and N221
ϩ T cells but not Con A-activated T cells or T cells specific for an unrelated Ag could suppress diabetes development.
of Con A-stimulated splenocytes and BDC2.5 cells stimulated with peptide using Abs against several different surface Ags. Briefly, Ͼ92% of the Con A-stimulated CD4 ϩ cells expressed CD5, CD25, CD44, CD45RB, CD62 ligand (L), and CD69, and some of these cells also expressed CD40 (ϳ37%) and CD40L (ϳ67%). Similarly, Ͼ92% of the peptide-stimulated BDC2.5 T cells expressed CD5, CD25, CD44, and CD69, and a majority of cells also expressed CD40 (ϳ77%), CD45RB (ϳ83%), and CD62L (ϳ67%). But only a small percentage of cells expressed CD40L. At least 10 animals were used in each transfer experiment. 
In vivo regulatory function of N206 ϩ and N221 ϩ cells
To determine the potential in vivo mechanisms of how the tetramer ϩ T cells may inhibit diabetes development in adoptive transfer experiments, we determined whether the tetramerϩ T cells could block the migration of the diabetogenic BDC2.5 T cells into lymph nodes after they were cotransferred into recipient animals. We did the adoptive transfer experiments in two different ways. First, we mixed and cotransferred the BDC2.5-transgenic mouse spleen cells with equal numbers of tetramer ϩ T cells into NOD/ scid mice. The presence of BDC2.5 T cells in the lymph nodes of recipient mice was monitored using the tetAg7/p79 tetramer. Our results demonstrated that, compared with that of mice receiving just the BDC2.5 splenocytes, the number of BDC2.5 cells (CD4 ϩ , tetAg7/p79 ϩ T cells) present in the lymph nodes of recipient mice was significantly reduced at 4 and 24 h after the transfer (Fig. 7A) . The number of BDC2.5 T cells in the lymph nodes was reduced 3-fold at both 4 and 24 h when they were cotransferred with the N206 ϩ cells, and was reduced 8-and 4-fold at 4 and 24 h, respectively, when they were cotransferred with N221 ϩ cells. Second, the tetramer ϩ T cells were preactivated by PMA/ionomycin and then incubated with BDC2.5 cells for 2 h at 37°C to find out whether incubation of BDC cells with activated tetramer ϩ cells may have a better inhibitory effect than nonactivated cells. The results showed that, like the nonactivated cells, activated tetramer ϩ cells also blocked the migration of BDC2.5 T cells into lymph nodes, except that the activated cells may result in a better effect at significantly reducing the number of BDC2.5 cells in lymph nodes at 24 h (10-and 12-fold for N206 ϩ cells and N221 ϩ cells, respectively; Fig. 7B ). Therefore, these results show that the tetramer ϩ T cells could block the migration of the diabetogenic BDC2.5 cells into lymph nodes. The results are also consistent with our data that there was essentially no insulitis detected in the protected mice.
Furthermore, by tracking the localization of the transferred tetramer ϩ cells, we found that the tetramer ϩ T cells could migrate into the lymph nodes and be detected at 4 and 24 h after the transfer (Fig. 7C) . The results showed that a significant number of both N206 ϩ and N221 ϩ cells were present in the lymph nodes at 4 h and that the number of tetramer ϩ cells increased at 24 h. Additionally, more N206 ϩ cells than N221 ϩ cells were present in the lymph nodes at 4 h, whereas more N221 ϩ cells than N206 ϩ cells were present in the nodes at 24 h. It is not known why these cells showed a different migration rate into lymph nodes and whether such a difference in migration and/or accumulation in lymph nodes may contribute to the difference in their effect on diabetes development. Altogether, these in vivo studies demonstrated that, in addition to suppressing the proliferation of other T cells as shown in the in vitro assays (see Figs. 8 and 9 ), inhibition of diabetogenic T cell migration could also be a mechanism of these tetramer ϩ regulatory T cells to inhibit diabetes development in recipient animals.
In vitro regulatory function of N206
ϩ and N221 ϩ cells
In addition to the in vivo adoptive transfer experiments, we further studied the in vitro regulatory function of N206 ϩ and N221 ϩ cells and determined whether they could suppress the proliferation of other T cells. First, N206 ϩ or N221 ϩ cells were cocultured with CFSE-labeled BDC2.5 T cells with or without p79, a peptide that is highly active in stimulating BDC2.5 cells (27) . After stimulated by p79 for 4 days, BDC2.5 cells could proliferate Ն3 rounds of cell division as shown by the decrease of CFSE intensity (Fig. 8) . However, BDC2.5 cell proliferation was suppressed in the presence of N206 ϩ or N221 ϩ cells and, therefore, more BDC2.5 cells still expressed higher intensity of CFSE and divided Ͻ3 rounds. Coculture of BDC2.5 cells with equal numbers of N206 ϩ (Fig. 8A ) or N221 ϩ (Fig. 8B ) cells activated with their antigenic peptides increased the percentage of cells that underwent Ͻ3 rounds of cell division from ϳ14 to 23% in the absence of tetramer ϩ cells to ϳ80 or ϳ70% in the presence of N206 ϩ or N221 ϩ cells, respectively. It is worth noting that, although most of the BDC2.5 cells have not divided when they were cocultured with tetramer ϩ cells, the total number of BDC2.5 cells are much lower than the number of cells present in the other cell cultures analyzed (Fig. 8) . Therefore, the results suggest that the N206 ϩ and N221 ϩ cells may have in some way decreased the total number of BDC2.5 cells in the culture, perhaps by cytotoxicity due to the release of cytokines.
We then wanted to know whether cell-cell contact between tetramer ϩ cells and target cells was necessary for their regulatory functions. We addressed this question using Transwell assays that tetramer ϩ T cells were cultured in a Transwell (upper well or UW) and separated from the target NOD splenocyte cultured outside of the Transwell in the lower well (LW). Both tetramer ϩ cells and NOD splenocytes were stimulated with PMA/ionomycin. The results showed that the proliferation of NOD splenocytes (5 ϫ 10 5 (Fig. 9, A and B) . The suppression effect was proportional to the number of activated tetramer ϩ cells present in the Transwell because splenocyte proliferation was further inhibited in the presence of more activated tetramer ϩ T cells. Therefore, the percent inhibition of splenocyte proliferation increased from an average of 32% in the presence of 2% N206 ϩ cells to 74.5% in the presence of 50% N206 ϩ cells (Table I) . Additionally, the percent inhibition of NOD mouse T cell proliferation increased from an average of 22.5% in the presence of 2% N221 ϩ cells to 70% in the presence of 50% N221 ϩ cells (Table I ). In summary, both N206 ϩ and N221 ϩ cells were able to suppress the proliferation of other NOD T cells, including diabetogenic T cells. Furthermore, they could perform their regulatory function without the need to be in contact with the target cells.
Blocking the regulatory function of N206
It has been shown that IL-4 and IL-10 can regulate autoimmune response (11, (37) (38) (39) (40) . Because both N206 ϩ and N221 ϩ T cells produced IL-4, IL-10, and IFN-␥, it is likely that these cells performed their regulatory function by secreting these cytokines. To find out whether this is true, we repeated the Transwell assays with the addition of saturating amount of Abs against IL-4, IL-10, and IFN-␥ in the cell culture. We included anti-IFN-␥ Ab in these assays because the tetramer ϩ T cells, especially the N221 ϩ cell, contained Tr1 cells that could produce a large amount of both IL-10 and IFN-␥. Additionally, it has not been shown before that autoantigen-specific Tr1 cells may play a role in diabetes development. Studies on N206 ϩ cells showed that anti-IL-10, and, to a lesser extent, anti-IFN-␥, but not anti-IL-4 Abs, could partially restore the proliferation of the NOD spleen target cells (Fig. 9C) .
Compared with that of cells cultured with N206
ϩ cells in the absence of the Abs, the proliferation of target cells increased 1.7-and 1.3-fold in the presence of anti-IL-10 and anti-IFN-␥ Abs, respectively ( Fig. 9C and Table II ). The use of a combination of two Abs against different cytokines did not result in a synergistic effect that further increased the target cell proliferation. Therefore, N206 ϩ cells may perform their regulatory function at least partly by secreting IL-10 and perhaps also IFN-␥. It is possible that another unknown factor(s) also plays a role for N206 ϩ cell to perform their regulatory functions.
On the other hand, all three Abs could partially increase the target cell proliferation suppressed by N221 ϩ cells (Fig. 9D and Table II) . Interestingly, anti-IFN-␥ Ab had the best effect and resulted in a 1.7-fold increase of target cell proliferation compared with that of cells cultured with N221 ϩ cells without the Ab. The presence of Abs against IL-4 and IL-10 had the same effect as that with just the anti-IL-10 Ab (Table II) . However, surprisingly, the presence of both anti-IL-10 and anti-IFN-␥ Abs resulted in a 2.6-fold increase of the target cell proliferation. Therefore, the presence of these two Abs not only fully restored but also enhanced the target cell proliferation by ϳ30% compared with that of cells cultured in the absence of N221 ϩ cells and Abs (Fig. 9D) . In summary, it appears that a majority of N221 ϩ cells and some N206 ϩ cells could function not only as Th2 cells but also as Tr1 regulatory T cells by secreting both IL-10 and IFN-␥.
Expression of CTLA-4 by a subpopulation of tetramer ϩ T cells
It has been shown that T cells expressing increased levels of CTLA-4 could regulate the function of other T cells (41) (42) (43) . Expression of higher levels of CTLA-4 has also been implicated as a potential mechanism that GAD peptide-specific T cells could perform their regulatory functions (44) . Therefore, although N206 ϩ and N221 ϩ cells could exert their regulatory functions through cytokine-mediated suppression rather than cell-cell contact, we also determined whether a subpopulation of the tetramer ϩ regulatory T cells expressed CTLA-4. We stained the N206 ϩ and N221 ϩ T cells with an anti-CTLA-4 Ab. The results showed that ϳ18.2% of N206 ϩ cells and ϳ17.1% N221 ϩ cells expressed CTLA-4 on the cell surface (Fig. 10) . Therefore, a subpopulation of these tetramer ϩ T cells did express CTLA-4.
Discussion
These studies show that treatment of NOD mice with autoantigenic peptides can induce Ag-specific CD4 ϩ regulatory T cells with cytokine secretion profiles that varied depending on the Ag specificity. Both N206 ϩ and N221 ϩ T cells were able to inhibit IDDM, which could be because these cells contained IL-4/IL-10 coproducing Th2 cells and IFN-␥/IL-10 coproducing Tr1 cells (15, 16, ϩ Th1 cells may counteract the effect of Th2 cells. It is likely that these differences between the function of N206 ϩ and N221 ϩ cells resulted in the different effect of N206 ϩ and N221 ϩ cells on IDDM development. Our results also showed that the cytokine secretion profile of the T cells from similarly treated BALB/c mice were different from that of NOD mouse tetramer ϩ T cells. Further studies to determine the cytokine secretion profiles of T cells before being restimulated and expanded in vitro showed that both p206-specific and p221-specific T cells isolated from GAD-immunized NOD mice, like the N206 ϩ and N221 ϩ cells, were biased toward IL-4-producing and IFN-␥-producing cells, respectively. On the other hand, we could not detect a significant cytokine secretion response by T cells derived from GAD-immunized BALB/c mice, suggesting that the frequency of such T cells was too low to be detected without further restimulation with the peptides in vitro. These studies suggest that the function of the tetramer ϩ T cells from NOD mice was probably polarized in vivo rather than in vitro during cell culture because the cells were cultured under the same conditions. Furthermore, N206 ϩ and N221 ϩ cells can also respond to the GAD protein presented by irradiated NOD splenic APCs, suggesting that these T cells are similar to those that develop spontaneously in NOD mice. Therefore, it seems that the properties of the tetramer ϩ Tr cells in vivo are similar to those observed in the in vitro analyses and that the atypical cytokine secretion profile of autoreactive T cells such as N221 ϩ and N206 ϩ cells is likely intrinsic to NOD mice. The reason for the differences seen in these animals is not clear but it may be due to the difference in I-Ad vs I-Ag7 molecules that could result in the selection of T cells with distinct functions. One might have predicted that BALB/c mouse T cells were more likely to become Th2 cells due to their genetic backgrounds (46, 47) . However, in addition to the difference in producing IFN-␥/IL-4, the B206 ϩ /B221 ϩ cells secreted more IL-2 but less IL-4/IL-10 than did N206 ϩ /N221 ϩ cells. It is likely that these differences are due to the unique features of I-Ag7 structure and its property in binding and presenting peptides or due to the nature of the autoantigen-MHC complex (48 -50) . Although the weaker IL-2 response may be interpreted as an indication that N206 ϩ / N221 ϩ cells bore TCRs of lower affinity than B206 ϩ /B221 ϩ cells for their ligands, it is not clear whether the same rationale can be applied to explain the differences in IL-4/IL-10 production. In addition, the decreased IL-2 secretion response of N206 ϩ and N221 ϩ cells is consistent with the notion that they contain Tr1 cells. Alternatively, the difference could be due to altered APCs in NOD mice (51, 52 ). An interesting finding in this report is that treatment of NOD mice using the GAD peptides could induce not only Th2 but also Tr1 regulatory T cells. The tetramer ϩ regulatory T cells not only could inhibit diabetes but could also suppress the proliferation of other T cells in vitro by secreting different cytokines, and their cell-cell contact with target cells was not required. Whereas one may expect that anti-IL-4 and anti-IL-10 Abs can inhibit the regulatory function of the tetramer ϩ cells, it is not clear why anti-IFN-␥ can also do so. Additionally, it is not clear why blocking both IFN-␥ and IL-10 not only restore but even enhance the NOD spleen cell proliferation suppressed by N221 ϩ cells. Previous studies on NOD mice deficient in IFN-␥, IL-10, or IL-4 expression showed that elimination of any one of these cytokines did not significantly alter the rate of IDDM development (53, 54) . However, it is not known whether NOD mice deficient in, e.g., both IFN-␥ and IL-10 expression, will have altered IDDM development. Interestingly, inhibition of IDDM development in NOD mice by the nonspecific immunostimulatory agents CFA or bacillus Calmette-Guérin vaccine treatment was dependent on the presence of IFN-␥ (54). Therefore, it is likely that IFN-␥ can be involved in the regulation of IDDM in NOD mice. Our studies to determine the potential in vivo mechanisms underlying the inhibition of diabetes development by the tetramer ϩ T cells showed that these regulatory T cells could block the migration of the diabetogenic BDC2.5 T cells into lymph nodes of recipient mice. This blocking effect may be reminiscent of the findings described in a recent report that low-dose IFN-␥ exerts anti-inflammatory properties, such as suppression of T cell trafficking (55) . Therefore, incubation of T cells in vitro with a low concentration of IFN-␥ blocked the migration of treated T cells into lymph nodes after they were adoptively transferred into recipient mice. In our studies, we have shown that both N206 ϩ and N221 ϩ regulatory T cells secreted IFN-␥. However, considering the amount of IFN-␥ produced by these tetramer ϩ Tr cells, it seems that this level of IFN-␥ is relatively low when compared with the higher concentration of IFN-␥ (ϳ100 ng/ml) normally secreted by Th1 cells. Therefore, the tetramer ϩ regulatory T cells may block the migration of BDC2.5 T cells because they secrete low concentrations of IFN-␥. Further studies should help determine whether these and other mechanisms are responsible for the blockade of BDC cell migration by the tetramer ϩ cells. In summary, these results suggest that, in addition to suppressing T cell proliferation as shown in the in vitro assays, inhibition of diabetogenic T cell migration into lymph nodes may be one of the in vivo regulatory mechanisms that the tetramer ϩ cells could inhibit diabetes development in recipient mice. These results are also consistent with our observations that essentially no insulitis was detected in the protected mice.
Our results show that both N221 ϩ cells and N206 ϩ cells contain Tr1 cells and can secrete not only IFN-␥ but also IL-10. Considering the suppressive effect of IL-10 (11), it is likely that secretion of both IL-10 and IFN-␥ may be required for the proper regulatory function of Tr1 cells, and blocking of both cytokines could abolish the regulatory function of these cells. It has not been shown before that autoantigen-specific Tr1 regulatory cells can inhibit autoimmune diabetes development. Our results demonstrate that the GAD peptide-specific Tr1 cells can be induced in NOD mice and they may also play a role in regulating the development of diabetes. Because Tr1 cells could inhibit not only Th1 but also Th2 cell responses, further studies are necessary to determine the relative roles of IL-4/IL-10-coproducing Th2 cells vs IFN-␥/IL-10-coproducing Tr1 cells in regulating diabetes development in NOD mice (11, 14, 54, 56) . Several different populations of CD4 ϩ T cells have been shown to regulate autoimmune diseases. These cells may be identified by their surface phenotype, e.g., CD25
ϩ , DX5 ϩ , or CD45RB low cells, or by unique cytokine profiles, e.g., Th2, Th3, and Tr1 cells (35, (37) (38) (39) (40) 57) . Although the Ag specificity of these cells is largely uncharacterized, peripheral tissue-specific autoantigens could be responsible for activating these cells for their function in vivo (58) . The tetramer ϩ regulatory T cells identified in the current studies were specific for different GAD peptides and expressed CD25 and low levels of CD45RB (data not shown). Interestingly, a subpopulation of the N206 ϩ and N221 ϩ T cells also expressed CTLA-4 on the cell surface, similar to the activated T cells specific for GAD p286 peptide in transgenic mice (44) . It has been shown that increased expression of CTLA-4 by T cells, such as the CD4 ϩ CD25 ϩ Tr cells, may regulate the function of other pathogenic T cells through TGF-␤ production (41, 42) . However, the role of CTLA-4 expression and TGF-␤ production by CD4 ϩ CD25 ϩ Tr cells in regulating the functions of other T cells has been controversial (43, 59) . It is likely that the CTLA-4 ϩ tetramer ϩ cells may exhibit regulatory functions through CTLA-4. However, our results showed that the tetramer ϩ T cells barely produced TGF-␤. Therefore, it seems that, if CTLA-4 plays a role, secretion of TGF-␤ is not a major mechanism by which the tetramer ϩ T cells exert their regulatory functions. Further studies to isolate and characterize the CTLA-4
ϩ tetramer ϩ T cells should allow us to determine their role in diabetes development. In addition, the N206 ϩ and N221 ϩ cells seem to be different from the CD4 ϩ , CD25
ϩ , or CD45RB low T cells. Although the tetramer ϩ cells expressed CD25, it may simply reflect their activation status. Furthermore, cell-cell contact with target cells was necessary for the regulatory function of CD4 ϩ CD25 ϩ cells but not for the tetramer ϩ cell. Based on the cytokine secretion profiles, it is likely that N206 ϩ and N221 ϩ T cells are also different from the other autoantigen-specific T cells described previously (14, 15, 44) . In those studies, the autoreactive T cells may be Th2 cells or they may secrete a distinct profile of cytokines. Based on the current studies and those of others, it appears that T cells specific for different GAD peptides can differ in their capacity in the induction of varied populations of T cells with different effects on diabetes development. These studies also demonstrate the potential feasibility of inducing Ag-specific regulatory T cells with a diabetesrelated autoantigen to prevent autoimmune diabetes.
